Tuesday, January 02, 2024 10:30:18 AM
$1.21 +0https://investorshub.advfn.com/boards/edit_msg.aspx?message_id=173543744.351 (+40.86%)
https://stockcharts.com/h-sc/ui?s=NGM
Ngm Biopharmaceuticals Confirmed It Received A Non-Binding Expression Of Interest From The Column Group Regarding Potential Acquisition Of All Outstanding Shares Of Common Stock Of The Company Not Already Owned By TCG In A Going-Private Transaction
BENZINGA
7:36 AM ET Jan-02-2024
NGM Biopharmaceuticals, Inc. (NGM.NaE) today confirmed that it has received a non-bindingexpression of interest dated December 28, 2023 (the "EOI") from The Column Group,
NGM Biopharmaceuticals, Inc. (NGM.NaE) today confirmed that it has received a non-bindingexpression of interest dated December 28, 2023 (the "EOI") from The Column Group, LP and certain affiliated investment funds and persons (collectively, "TCG"), outlining TCG's intent to explore and evaluate a potential acquisition of all of the outstanding shares of common stock of the Company not already owned by TCG in a going-private transaction. TCG currently beneficially owns approximately 26.7% of the outstanding shares of NGM Bio's common stock. A copy of the EOI is attached to TCG's amended Schedule 13D filed with the Securities and Exchange Commission on December 29, 2023.
In response to the EOI, the Company's Board of Directors has formed a special committee consisting of disinterested and independent directors to consider the EOI and any other strategic alternatives that may be available to the Company, including remaining a standalone publicly-traded company. The special committee has retained Hogan Lovells US LLP as its independent legal advisor, and intends to retain an independent financial advisor, to assist it in considering the EOI. Cooley LLP is acting as legal advisor to the Company.
Recent NGM News
- NGM Bio Announces Closing of Tender Offer • GlobeNewswire Inc. • 04/05/2024 01:19:51 PM
- NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting • GlobeNewswire Inc. • 03/19/2024 09:30:44 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2024 08:15:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:13:03 PM
- NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/11/2024 08:05:00 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 03/08/2024 10:32:53 PM
- Form SC 14D9 - Solicitation, recommendation statements • Edgar (US Regulatory) • 03/08/2024 10:21:26 PM
- Form SC14D9C - Written communication relating to third party tender offer • Edgar (US Regulatory) • 02/26/2024 10:11:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 10:01:00 PM
- NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP • GlobeNewswire Inc. • 02/26/2024 02:03:59 PM
- NGM Bio to Participate in the Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/20/2024 09:01:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:12:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 11:09:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 11:03:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 11:02:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 11:01:27 PM
- NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference • GlobeNewswire Inc. • 01/17/2024 09:47:32 PM
- NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 12:30:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 10:19:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/04/2023 09:27:06 PM
- NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® • GlobeNewswire Inc. • 11/13/2023 02:45:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/08/2023 11:13:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/08/2023 11:11:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/08/2023 11:09:09 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM